International Immunopharmacology, Год журнала: 2024, Номер 144, С. 113675 - 113675
Опубликована: Ноя. 27, 2024
Язык: Английский
Molecular Biotechnology, Год журнала: 2024, Номер unknown
Опубликована: Март 8, 2024
Язык: Английский
Процитировано
7
Journal of Gastrointestinal Cancer, Год журнала: 2024, Номер 55(3), С. 990 - 1003
Опубликована: Май 2, 2024
Язык: Английский
Процитировано
6
Medicina, Год журнала: 2024, Номер 60(7), С. 1070 - 1070
Опубликована: Июнь 28, 2024
Pancreatic ductal adenocarcinoma (PDAC) ranks among the 15 most prevalent cancers globally, characterized by aggressive growth and late-stage diagnosis. Advances in imaging surgical techniques have redefined classification of pancreatic PDAC into resectable, borderline locally advanced cancer. While surgery remains effective treatment, only 20% patients are eligible at diagnosis, necessitating innovative strategies to improve outcomes. Therefore, traditional treatment paradigms, primarily resection for patients, increasingly supplemented neoadjuvant therapies (NAT), which include chemotherapy, radiotherapy, or a combination both. By administering systemic therapy prior surgery, NAT aims reduce tumor size increase feasibility complete resection, thus enhancing overall survival rates potentially allowing more undergo curative surgeries. Recent advances protocols, such as FOLFIRINOX gemcitabine-nab-paclitaxel, now integral strategies, shown promising results increasing proportion effectively reducing addressing micrometastatic disease. Additionally, they offer improved response benefits compared regimes. Despite these advancements, role continues evolve, ongoing research optimize regimens, minimize adverse effects, identify patient populations that would benefit from approaches. Through detailed analysis current literature recent clinical trials, this review highlights transformative potential managing PDAC, especially with resectable stages, shift towards personalized management PDAC.
Язык: Английский
Процитировано
6
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Май 22, 2024
The tumor microenvironment is closely linked to the initiation, promotion, and progression of solid tumors. Among its constitutions, immunologic cells emerge as critical players, facilitating immune evasion progression. Apart from their indirect impact on anti-tumor immunity, immunocytes directly influence neoplastic cells, either bolstering or impeding advancement. However, current therapeutic modalities aimed at alleviating immunosuppression regulatory effector cell populations may not consistently yield satisfactory results in various tumors, such breast carcinoma, colorectal cancer, etc. Therefore, this review outlines summarizes direct, dualistic effects T innate lymphoid B eosinophils, tumor-associated macrophages within microenvironment. also delves into underlying mechanisms involved presents outcomes clinical trials based these direct effects, aiming propose innovative efficacious strategies for addressing
Язык: Английский
Процитировано
5
Cytotherapy, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
International Journal of Biological Macromolecules, Год журнала: 2025, Номер 297, С. 139829 - 139829
Опубликована: Янв. 13, 2025
Язык: Английский
Процитировано
0
Expert Opinion on Investigational Drugs, Год журнала: 2025, Номер unknown, С. 1 - 12
Опубликована: Фев. 27, 2025
Introduction Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited therapeutic options and poor overall survival. In recent years, advances in genomic profiling have revealed the complex molecular cellular heterogeneity of PDAC, offering new avenues for intervention.
Язык: Английский
Процитировано
0
Exploration of Targeted Anti-tumor Therapy, Год журнала: 2025, Номер 6
Опубликована: Март 18, 2025
Pancreatic cancer is a challenging disease with limited treatment options and high mortality rate. Just few therapy advances have been made in recent years. Tumor microenvironment, immunosuppressive features mutational status represent important obstacles the improvement of survival outcomes. Up to now, first-line did achieve median overall less than 12 months this discouraging data lead clinicians all over world focus their efforts on various fields investigation: 1) sequential cycling different systemic order overcome mechanisms resistance; 2) discovery new predictive bio-markers, target specific patient population; 3) combination treatment, modulate tumor microenvironment pancreatic cancer; 4) modalities delivery drugs pass physical barrier desmoplasia stroma. This review shows future directions strategies advanced through deep analysis these macro areas research.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2024, Номер 16(15), С. 2630 - 2630
Опубликована: Июль 24, 2024
Lck, a member of the Src kinase family, is non-receptor tyrosine involved in immune cell activation, antigen recognition, tumor growth, and cytotoxic response. The enzyme has usually been linked to T lymphocyte activation upon recognition. Lck central CD4, CD8, NK activation. However, recently, it become clearer that activating CD8 cells can be independent presentation enhance role function controversial similar fashion as CAR cells. Inhibiting kinases highly successful approach treating hematologic malignancies. inhibitors may useful other types, they prevent exhaustion. New, more selective have documented, shown interesting activities not only growth but treatment autoimmune diseases, asthma, graft vs. host disease. Drug repurposing bioinformatics aid solving several unsolved issues about cancer. In summary, response simple event requires research.
Язык: Английский
Процитировано
2
Human Gene, Год журнала: 2024, Номер 41, С. 201307 - 201307
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
1